Revolution Medicines Facing Further Upside After Daraxonrasib's Results, RBC Says

MT Newswires Live04-14

Revolution Medicines (RVMD) has several paths toward additional upside on potential M&A deals and a launch following the release of phase 3 data on its experimental anti-cancer drug daraxonrasib, RBC Capital Markets said in a note Monday.

The investment firm said that Revolution "had always been planning for success," with no immediate changes to the company's pipeline or plans expected. The company is preparing for commercialization and continues to have high confidence in its clinical programs, according to the note.

Given Revolution's "history of moving quickly and efficiently," the investment firm said it expects a potential launch in H2 with no regulatory or operational challenges.

The release of the trial results may also place Revolution "back into takeout baskets" following unconfirmed media reports this year of AbbVie (ABBV) and Merck's (MRK) potential interest in the company, RBC said.

RBC has an outperform rating on Revolution and lifted the company's price target to $162 from $140.

Price: 143.00, Change: +6.70, Percent Change: +4.92

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment